Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance.

MLA

Dodds, H. M., et al. “Clinical Pharmacokinetics of the Irinotecan Metabolite 4-Piperidinopiperidine and Its Possible Clinical Importance.” Cancer Chemotherapy and Pharmacology, vol. 45, no. 1, 2000, pp. 9–14. EBSCOhost, https://doi.org/10.1007/PL00006750.

APA

Dodds, H. M., Clarke, S. J., Findlay, M., Bishop, J. F., Robert, J., & Rivory, L. P. (2000). Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. Cancer Chemotherapy and Pharmacology, 45(1), 9–14. https://doi.org/10.1007/PL00006750

Chicago

Dodds, H M, S J Clarke, M Findlay, J F Bishop, J Robert, and L P Rivory. 2000. “Clinical Pharmacokinetics of the Irinotecan Metabolite 4-Piperidinopiperidine and Its Possible Clinical Importance.” Cancer Chemotherapy and Pharmacology 45 (1): 9–14. doi:10.1007/PL00006750.